ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

What Is and Isn’t a Crime in Texas: CPRIT Official Indicted For Skipping Peer Review

December 13, 2013

Opening Shots Fired In 10 Year Defense of Cancer Program, Launching Of Effort To Continue, Expand It

September 19, 1980

Bristol-Myers Adds Georgetown, MSK to Program

May 1, 1981

Medicare Should Pay Routine Care For Patients in Trials: IOM.

January 7, 2000

ORI Misconduct Findings Announced In Two Cases

July 12, 1996

Genentech: ODAC Lacks Expertise, Impartiality; FDA: Company’s Proposal Unscientific

August 12, 2011